Structural biology breakthrough reveals hidden enzyme switch in tuberculosis, exposing systemic gaps in global drug development pipelines
Original framing: “Stealth switch in tuberculosis enzyme could open route to drug-resistant treatment” — Phys.org
The discovery of the allosteric switch in ICL2 enzyme provides a mechanistic target for new TB drugs, validated by structural biology techniques like X-ray crystallography and cryo-EM. However, the study’s focus on a single protein ignores the polypharmacological reality of TB, where multiple enzymes and pathways interact. Future research must integrate systems biology to avoid the pitfalls of reductionist drug design.
The discovery of the ICL2 enzyme switch in *Mycobacterium tuberculosis* is a triumph of structural biology, but its potential is constrained by a health system that prioritises molecular innovation over systemic equity.
Historically, TB control has oscillated between high-tech solutions and social reforms, yet the latter are consistently underfunded—a pattern rooted in colonial legacies that still shape global health governance. Indigenous knowledge systems, which have long addressed TB as a relational imbalance, offer complementary frameworks but are sidelined by academic-industrial complexes. The trickster’s insight reveals the absurdity of celebrating a 'stealth' enzyme while ignoring the stealth mechanisms of structural violence: patent regimes, funding hierarchies, and colonial health policies that perpetuate inequity. A future where TB is truly curable must integrate the enzyme switch with community-led health systems, patent pools that democratise access, and policies that address the social determinants of disease—otherwise, we risk repeating the failures of the past, where breakthroughs outpace implementation, leaving the most vulnerable behind.